G1 Therapeutics, Inc. - Common Stock (NQ:GTHX)

7.150 UNCHANGED

Last Price Updated: 4:00 PM EDT, Sep 17, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about G1 Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Nasdaq Turns Lower; Crude Oil Down Over 3% ↗

November 18, 2022

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite turning lower on Friday.

Via Benzinga

Delta Apparel, Farfetch, American Software And Some Other Big Stocks Moving Lower On Friday ↗

November 18, 2022

U.S. stocks traded mixed, with the Dow Jones gaining more than 80 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 18, 2022

Via Benzinga

Why Farfetch Shares Are Trading Lower; Here Are 26 Stocks Moving Premarket ↗

November 18, 2022

Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares rose 58.1% to $2.45 in pre-market trading. PaxMedica entered into committed equity investment agreement for up to $20 million with Lincoln Park Capital.

Via Benzinga

G1 Therapeutics: Q3 Earnings Insights ↗

November 02, 2022

G1 Therapeutics (NASDAQ:GTHX) reported its Q3 earnings results on Wednesday, November 2, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

G1 Therapeutics Return On Capital Employed Insights ↗

August 10, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

November 18, 2022

It's time to start closing out the trading week with a dive into the biggest pre-market stock movers for Friday morning!

Via InvestorPlace

G1 Therapeutics Announces Pricing of Offering of Common Stock

November 17, 2022

From G1 Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 17, 2022

Via Benzinga

G1 Therapeutics Announces Proposed Public Offering of Common Stock

November 17, 2022

From G1 Therapeutics

Via GlobeNewswire

G1 Therapeutics: Q2 Earnings Insights ↗

August 03, 2022

G1 Therapeutics (NASDAQ:GTHX) reported its Q2 earnings results on Wednesday, August 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

G1 Therapeutics: Q1 Earnings Insights ↗

May 04, 2022

G1 Therapeutics (NASDAQ:GTHX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday ↗

November 03, 2022

Gainers Starry Group Holdings, Inc. (NYSE: STRY) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results.

Via Benzinga

Analyst Ratings For G1 Therapeutics ↗

November 04, 2021

Analysts have provided the following ratings for G1 Therapeutics (NASDAQ:GTHX

Via Benzinga

Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Session ↗

November 02, 2022

Gainers Starry Group Holdings, Inc. (NYSE: STRY) gained 56% to $0.2808 after reporting Q3 results.

Via Benzinga

G1 Therapeutics Says Its Lead Candidate May Cut Adverse Events Of Gilead's Breast Cancer Drug ↗

November 02, 2022

Via Benzinga

G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights

November 02, 2022

From G1 Therapeutics

Via GlobeNewswire

Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC)

November 02, 2022

- Data Suggest On-Target Effect of Trilaciclib May Reduce Rates of Myelosuppression, Diarrhea, and Potentially Alopecia Associated with Sacituzumab Govitecan-Hziy -

From G1 Therapeutics

Via GlobeNewswire

G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)

October 10, 2022

From G1 Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

August 08, 2022

Via Benzinga

Week In Review: WuXi Biologics And WuXi AppTec Plan $2.8 Billion Investment In Singapore Facilities ↗

July 23, 2022

WuXi Biologics and WuXi AppTec announced that each company would invest $1.4 billion over ten years to build R&D and manufacturing facilities in Singapore. Frontera Therapeutics completed a $160...

Via Talk Markets

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

July 14, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

July 13, 2022

Via Benzinga

Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday ↗

August 08, 2022

Gainers

Via Benzinga

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗

May 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗

February 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

March 16, 2022

On Wednesday, 90 companies set new 52-week lows. Areas of Significance In Today's 52-Week Lows: The company with the largest market cap to set a new 52-week low was...

Via Benzinga

G1 Therapeutics: Q4 Earnings Insights ↗

February 23, 2022

G1 Therapeutics (NASDAQ:GTHX) reported its Q4 earnings results on Wednesday, February 23, 2022 at 06:30 AM. Here's what investors need to know about the announcement....

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2021 ↗

November 04, 2021

Upgrades According to B. Riley Securities, the prior rating for Monroe Capital Corp (NASDAQ:

Via Benzinga

G1 Therapeutics, Inc (GTHX) Q3 2021 Earnings Call Transcript ↗

November 03, 2021

GTHX earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.